MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
series e preferred...
$5,000,000
Proceeds from issuance of
convertible notes payable
$250,000
Net cash provided by
financing activities
$4,487,426
Canceled cashflow
$762,574
Increase (decrease) in
cash and cash...
$3,193,112
Canceled cashflow
$1,294,314
Offering costs
$762,574
Loss on issuance of
convertible note
-$322,359
Amortization of debt discount
$240,370
Change in fair value of
derivative liability
-$148,766
Stock based
compensation
$128,440
Accounts payable
$111,941
Issuance of shares for
services
$100,000
Deferred revenue
$31,035
Interest payable
$26,634
Depreciation and
amortization
$12,306
Inventory
-$11,694
Amortization of license fees
$5,625
Net cash used in
operating activities
-$1,288,960
Net cash used in
investing activities
-$5,354
Canceled cashflow
$1,139,170
Net loss
-$2,174,836
Purchases of intangible
assets, including...
$5,354
Accrued liabilities
-$202,448
Prepaid expenses and
other assets
$46,199
Amortization of right-of-use
assets, net of...
$3,120
Accounts receivable
$1,527
Back
Back
Cash Flow
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)
source: myfinsight.com